ImmunoGen Inc - ESG Rating & Company Profile powered by AI
This analysis of ImmunoGen Inc leverages information from across the internet and also from available disclosures by ImmunoGen Inc. This article contains a questions and answers table for ImmunoGen Inc. Detailed ESG assessment of ImmunoGen Inc are accessed by logging in.
ImmunoGen Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.9; made up of an environmental score of 2.0, social score of 4.8 and governance score of 4.8.
3.9
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 1004 | Xeris Pharmaceuticals Inc | 4.0 | High |
| 1004 | Xenon Pharmaceuticals Inc | 4.0 | High |
| ... | ... | ... | |
| 1089 | ImmunoGen Inc | 3.9 | Medium |
| 1089 | Aclaris Therapeutics Inc | 3.9 | Medium |
| 1089 | Allogene Therapeutics Inc | 3.9 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does ImmunoGen Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes ImmunoGen Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes ImmunoGen Inc report the average age of the workforce?
Sign up for free to unlockDoes ImmunoGen Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes ImmunoGen Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes ImmunoGen Inc disclose cybersecurity risks?
Sign up for free to unlockDoes ImmunoGen Inc offer flexible work?
Sign up for free to unlockDoes ImmunoGen Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes ImmunoGen Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes ImmunoGen Inc conduct supply chain audits?
Sign up for free to unlockDoes ImmunoGen Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes ImmunoGen Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes ImmunoGen Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes ImmunoGen Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes ImmunoGen Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes ImmunoGen Inc disclose water use targets?
Sign up for free to unlockDoes ImmunoGen Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid ImmunoGen Inc have a product recall in the last two years?
Sign up for free to unlockDoes ImmunoGen Inc disclose incidents of discrimination?
Sign up for free to unlockDoes ImmunoGen Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas ImmunoGen Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes ImmunoGen Inc disclose parental leave metrics?
Sign up for free to unlockDoes ImmunoGen Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes ImmunoGen Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes ImmunoGen Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes ImmunoGen Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes ImmunoGen Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes ImmunoGen Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs ImmunoGen Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes ImmunoGen Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes ImmunoGen Inc disclose its waste policy?
Sign up for free to unlockDoes ImmunoGen Inc report according to TCFD requirements?
Sign up for free to unlockDoes ImmunoGen Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes ImmunoGen Inc disclose energy use targets?
Sign up for free to unlockDoes ImmunoGen Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes ImmunoGen Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for ImmunoGen Inc
These potential risks are based on the size, segment and geographies of the company.
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.